Trailing-twelve-month (TTM) revenue is $2.95 Billion with a year-over-year growth of +5.52%. Revenue represents the total income generated from the company's primary business operations.
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $705,873,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-10-24 |
| Q4 FY2025Period ended 2025-12-31 | $719,402,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-02-03 |
| Q1 FY2026Period ended 2026-03-31 | $752,952,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-06 |
| Q2 FY2026Period ended 2026-06-30 | $771,579,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-05 |
| TTM revenue | $2,949,806,000 |
Current P/S: $14,002,120,200 market capitalization ÷ $2,949,806,000 TTM revenue = 4.75x.
Market capitalization source: FMP quote. Quote observed 2026-09-25T20:00:02.000Z. Latest revenue period ended 2026-06-30.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
Reported quarterly revenue; no daily interpolation. Q2 FY2026 (2026-06-30): $771.58M.
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-09-26T00:15:41.402Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-09-11.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20252025-12-31 · USD |
|---|---|
| Lab | $860M |
| Outpatient Medical Buildings | $1.3B |
| Senior Housing | $604M |
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20252025-12-31 · USD |
|---|---|
| Lab | $860M |
| Outpatient Medical Buildings | $1.3B |
| Senior Housing | $604M |
$2.95B
$2.95 Billion
+5.52%
vs. $2.80B a year ago (TTM)
+19.15%
5 Year compound annual growth rate
1 Year
+5.52%
3 Year
+11.71%
5 Year
+19.15%
10 Year
+2.15%
15 Year
N/A
20 Year
N/A
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2025 | $2.82B | +$122.06M | +4.52% |
| 2024 | $2.70B | +$519.45M | +23.82% |
| 2023 | $2.18B | +$119.83M | +5.81% |
| 2022 | $2.06B | +$164.99M | +8.70% |
| 2021 | $1.90B | +$251.31M | +15.28% |
| 2020 |
TTM Growth
+5.52%
3-Year CAGR
+11.71%
5-Year CAGR
+19.15%
Revenue growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
Current FMP quote-based enterprise value / four-quarter revenue Quote observation: 2026-09-26T00:15:41.402Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-09-11.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
| $1.64B |
| +$404.54M |
| +32.61% |
| 2019 | $1.24B | +$49.02M | +4.11% |
| 2018 | $1.19B | ($657.06M) | (35.55%) |
| 2017 | $1.85B | ($280.92M) | (13.19%) |
| 2016 | $2.13B | +$188.81M | +9.73% |
